Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A

International Journal of Cancer

Volumn 85, Issue 5, 2000, Pages 710-715

  Ciardiello, Fortunato ^a   Caputo, Rosa ^a   Pomatico, Grazia ^a   De Laurentiis, Michelino ^a   De Placido, Sabino ^a   Bianco, A Raffaele ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GYRASE INHIBITOR; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CARBOPLATIN; CELL DIVISION; CELL LINE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CISPLATIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; EPITHELIAL CELLS; ETOPOSIDE; FEMALE; GENES, ERBB-2; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PACLITAXEL; RECEPTOR, ERBB-2; TAXOIDS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0033966434     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000301)85:5<710::AID-IJC18>3.0.CO;2-4     Document Type: Article

References (25)

1. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. clin. Oncol., 14, 737-744 (1996).
2. CARLOMAGNO, C., PERRONE, F., GALLO, C., DE LAURENTIIS, M., LAURIA, R., MORABITO, A., PETTINATO, G., PANICO, L., D'ANTONIO, A., BIANCO, A.R. and DE PLACIDO, S. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. clin. Oncol., 14, 2702-2708 (1996).
3. CHEN, H., NESS, E., MARSHALL, J., MARTIN, R., DVORCHIK, R., RIZVI, N., MARQUIS, J., DAHUT, W. and HAWKINS, M.J. Phase I trial of a second generation oligonucleotide (GEM 231) targeted al type I protein kinase A in patients with refractory solid tumors. Proc. Amer. Soc. clin. Oncol., 18, 610 (1999).
4. CIARDIELLO, F., GOTTARDIS, M., BASOLO, F., PEPE, S., NORMANNO, N., DICKSON, R.B., BIANCO, A.R. and SALOMON, D.S. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-α genes on in vitro transformation of human mammary epithelial cells. Mol. Carcinogenesis, 6, 43-52 (1992).
5. CIARDIELLO, F., and 13 OTHERS, Transforming growth factor-α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras proto-oncogene but not by the c-neu proto-oncogene, and overexpression of the transforming growth factor-α complementary DNA leads to transformation. Cell Growth Differentiation, 1, 407-420 (1990).
6. CIARDIELLO, F., PEPE, S., BIANCO, C., BALDASSARRE, G., RUGGIERO, A., BIANCO, C., SELVAM, M.P., BIANCO, A.R. and TORTORA, G. Down-regulation of R1α subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer, 53, 438-443 (1993).
7. CIARDIELLO, F. and TORTORA, G. Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications. Clin. Cancer Res., 4, 821-828 (1998).
8. DICKSTEIN, B.M., WOSIKOWSKI, K. and BATES, S.E. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110, 205-211 (1995).
9. HARRIS, L.N., YANG, L., TANG, C., YANG, D. and LUPU, R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clin. Cancer Res., 4, 1005-1012 (1998).
10. MENDELSOHN, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3, 2703-2707 (1997).
11. MENDELSOHN, J. and FAN, Z. Epidermal growth factor receptor family and chemosensitization. J. natl. Cancer Inst., 89, 341-343 (1997).
12. NICHOLSON, S., WRIGHT, C., SAINSBURY, R.C., HALCROW, P., KELLY, P., ANGUS, B., FARNDON, J.R. and HARRIS, A.L. Epidermal growth factor receptor as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J. Steroid Biochem. mol. Biol. 37, 811-814 (1990).
13. PAIK, S., BRYANT, J., PARK, C., FISHER. B., TAN-CHIU, E., HYAMS, D., FISHER, E.R., LIPPMAN, M.E., WICKERHAM, D.L. and WOLMARK, N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. natl. Cancer Inst., 90, 1361-1370 (1998).
14. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. clin. Oncol., 16, 2659-2671 (1998b).
15. PEREZ, E.A. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control, 6, 233-240 (1999).
16. SALOMON, D.S, BRANDT, R., CIARDIELLO, F. and NORMANNO, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183-232 (1995).
17. SRIVASTAVA, R., SRIVASTAVA, A., KORSMEYER, S.J., NESTEROVA, M., CHO-CHUNG, Y.S. and LONGO, D.L. Involvement of microtubules in the regulation of b12 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. cell. Biol., 18, 3509-3517 (1998).
18. THOR, A.D., BERRY, D.A., BUDMAN, D.R., MUSS, H.B., KUTE, T., HENDERSON, I.C., BARCOS, M., CIRRINCIONE, C., EDGERTON, S., ALLRED, C., NORTON, L. and LIU, E.T. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J natl. Cancer Inst., 90, 1346-1360 (1998).
19. TORTORA, G., CAPUTO, R., DAMIANO, V., BIANCO, R., PEPE, S., BIANCO, A.R., JIANG, Z., AGRAWAL, S. and TORTORA, G. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone anti-sense oligonucleotide targeting protein kinase A. Proc. natl. Acad. Sci. (Wash.), 94, 12586-12591 (1997).
20. TORTORA, G., CAPUTO, R., POMATICO, G., PEPE, S., BIANCO, A.R., AGRAWAL, S., MENDELSOHN, J. and CIARDIELLO, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5, 875-881 (1999).
21. TORTORA, G., CIARDIELLO, F., DAMIANO, V., PEPE, S., BIANCO, C., DI ISERNIA, G., DAVIES, S.L., NORTH, P., HARRIS, A.L., HICKSON, J.D. and BIANCO, A.R. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. Clin. Cancer Res., 1, 49-56 (1995).
22. YOKOZAKI, H., BUDILLON, A., TORTORA, G., MEISSNER, S., BEAUCAGE, S.L., MIKI, K. and CHO-CHUNG, Y. S. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res., 53, 868-872 (1993).
23. mdr 1 renders breast cancer cells highly resistant to taxol. Oncogene, 16, 2087-2094 (1998).
24. WOSIKOWSKI, K., SCHUURUIS, D., KOPS, G.J.P.L., SACEDA, M. and BATES, S.E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res., 3, 2405-2414 (1997).
25. WRIGHT, C., NICHOLSON, S., ANGUS, B., SAINSBURY, J.R.C., FARNDON, J., CAIRNS, J., HARRIS, A.L. and HORNE, C.H.W. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Brit. J. Cancer, 65, 118-121 (1992).